AGRF Expands Olink® Platform with Signature Q100, Boosting Biomarker Discovery and Prognosis Capabilities
/Media Release
AGRF is thrilled to announce the expansion of its Olink® fleet with the addition of the Olink Signature Q100. This platform joins our certified Olink Explore HT and Explore 3072 workflows, further enhancing our ability to deliver comprehensive proteomic analyses. Through a valued collaboration with The Kids Research Institute Australia (The Kids) in Perth, which has funded the platform, this exciting new service will be operated by AGRF and is set to offer significant new opportunities for researchers across multiple disciplines.
The Olink Signature Q100 allows us to run the Olink Target 96 and 48 workflows, enabling researchers with both absolute and relative quantitative proteomic data, driving the identification and validation of biomarkers from early discovery to implementation and disease risk prediction. It is a powerful tool for advancing research in diverse areas of human health and disease such as cancer, cardiovascular diseases, and immune disorders.
Samuel Montgomery, Research Officer at The Kids, said the new equipment would be particularly useful for paediatric research as it could measure panels of proteins in very small sample volumes. “Biological samples from children are often very small and this equipment will allow researchers to perform protein assays from these limited sample volumes for projects in respiratory, cancer, precision health, rare diseases and infectious disease research.”
Desley Pitcher, Head of Sales at AGRF, emphasised the importance of this collaboration: "Our valuable collaboration with The Kids Research Institute Australia has allowed us to expand our capabilities beyond exploratory proteomics and now enables our clients to focus in on profiling key disease markers, particularly in immunology. We are proud to partner with The Kids and support their world class research efforts to improve health outcomes for children.
Dr Benjamin Cooper, Technical Officer at AGRF, commented on the platform’s integration: “Proteomics has entered an exciting time, creating terrific opportunities for novel and high-impact research into many areas of biology. The adoption of the Target/Flex/Focus workflows using the Q100 greatly expands the flexibility of AGRF’s proteomic offering, helping drive translational outcomes.”
With the addition of the Olink Signature Q100, AGRF continues to lead the way in supporting cutting-edge proteomic and genomic research, enabling scientists to push the boundaries of human health and precision medicine.
AGRF continues its commitment to being at the forefront of proteomic and genomic services, providing world-class support to researchers in Australia and beyond.
